Research
Mizuho Initiates Zentalis Pharmaceuticals at Outperform With $8 Price Target
Zentalis Pharmaceuticals (ZNTL) has an average rating of overweight and mean price target of $6.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
$ZNTL
